FibroGen, Inc

Good day and thank you for standing by. Welcome to the FibroGen second quarter 2023 earnings call. At this time, all participants are in listen-only mode. After the speaker's presentation, there'll be a question and answer session. To ask a question during the session, you will need to press star 1 1 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 1 1 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, David DeLucia. Please go ahead.

Good afternoon, everyone. Thank you for joining today to discuss our second quarter 2023 financial and business results. I'm David DeLucia, Vice President of Corporate FP&A and Investor Relations at FibreJump. Joining me on today's call are Thayne Weddick, our Interim Chief Executive Officer, Juan Graham, our Chief Financial Officer, Dr. Mark Eisner, our Chief Medical Officer, Dr. John Hunter, our Chief Scientific Officer, Chris Chung, our Senior Vice President of China Operations, and Enrique Quintero, our Outgoing Chief Executive Officer. Following our prepared remarks, we will open the call to your questions. I would like to remind you that remarks made on today's call include forward-looking statements about FiberGem. Such statements may include but are not limited to our collaborations with AstraZeneca and Astellas, financial guidance, the initiation, enrollment, design, conduct, and results of clinical trials, our regulatory strategies and potential regulatory results, our research and development activities, commercial results and results of operations, risks related to our business, and certain other business matters. Each forward-looking statement is subject to risks and uncertainties that could cause actual results and events to differ materially from those projected in that statement. A more complete description of these and other material risks can be found in FibroGen's filings with the SEC, including our most recent Form 10-K and Form 10-Q. FibroGen does not undertake any obligation to update publicly any forward-looking statements, whether as a result of new information, future events, or otherwise. The press release reporting our financial results and business update and a webcast of today's conference call can be found on the investor section of FibreGen's website at www.fibregen.com. With that, I would like to turn the call over to Enrique Conterno.

Thank you, Dave, and good afternoon, everyone. First, I would like to take a moment to thank my FibreGen colleagues. Thank you. for your commitment and dedication during my tenure as CEO. It is important for me to highlight that despite the setback we have recently faced, I remain enthusiastic about FibroGen's opportunities, given our remaining near-term readouts from our Pembrevlima trials with Duchenne muscular dystrophy and pancreatic cancer, a thriving Roxadusta business in China, and our exciting early stage pipeline. Furthermore, we have a strong cash position that allows us to see through the evolution of our pipeline, as well as a talented team across the board. I am proud of the quality of our leadership team and delighted that Zane will be leading Fibrogen as interim CEO. I have known Zane for over 25 years and have worked closely with him at Fibrogen during his three years as chief commercial officer and at Lilly for about 10 years in his capacity as chief marketing officer for Lilly Diabetes, where he launched several blockbuster medicines during a period of unprecedented growth of Lilly's diabetes business. During our times working together, I have appreciated his excellent judgment, keen business instincts, and ability to lead organizations effectively. So without further delay, I'd like to pass the call to Mr. Thayne Weddick.